What is Polaramine
Dexchlorpheniramine maleateThe Generic name of this drug
Treatment SummaryDexchlorpheniramine is a type of anti-histamine used to treat allergy symptoms. It is a single form of the drug chlorpheniramine, which is more powerful and effective than other forms.
Dexchlorpheniramine Maleateis the brand name
Polaramine Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Dexchlorpheniramine Maleate
Dexchlorpheniramine maleate
1984
4
Approved as Treatment by the FDA
Dexchlorpheniramine maleate, also known as Dexchlorpheniramine Maleate, is approved by the FDA for 7 uses which include Vasomotor Rhinitis and Allergic Conjunctivitis (AC) .Vasomotor Rhinitis
Helps manage Vasomotor Rhinitis
Allergic Conjunctivitis (AC)
Helps manage Allergic Conjunctivitis (AC)
Hives
Helps manage Urticaria
Dermographism
Helps manage Dermographism
Allergic Reaction
Angioedema
Helps manage Angioedema
Catarrh
Effectiveness
How Polaramine Affects PatientsAllergic reactions occur when allergens attach to IgE antibodies on mast cells and basophils. This triggers the release of histamine and other chemicals, which can cause itching, flushing, headaches, and other symptoms. Dexchlorpheniramine is a drug that helps relieve these symptoms by blocking histamine from attaching to H1-receptors. It can provide temporary relief from sneezing, itchy eyes, runny nose and other issues caused by hay fever and allergies.
How Polaramine works in the bodyDexchlorpheniramine blocks the effects of histamine, which is a chemical that can cause swelling, itching, and other reactions. It does this by competing with histamine for sites on cells in the gut, blood vessels, and airways. Dexchlorpheniramine is more effective than regular chlorpheniramine in blocking histamine.
When to interrupt dosage
The recommended amount of Polaramine is contingent upon the determined circumstance, including Allergic Conjunctivitis (AC), Angioedema and Hay Fever. The dosage is contingent upon the mode of administration as stated in the table below.Condition
Dosage
Administration
Allergy
1.0 mg/mL, , 3.0 mg, 0.5 mg/mL, 2.0 mg/mL, 1.0 mg, 2.0 mg, 6.0 mg
Liquid - Oral, , Oral, Liquid, Tablet - Oral, Tablet, Syrup - Oral, Syrup, Solution / drops - Oral, Tablet, multilayer, Solution - Oral, Solution, Tablet, coated, Tablet, multilayer - Oral, Tablet, multilayer, extended release, Tablet, extended release - Oral, Tablet, coated - Oral, Solution / drops, Tablet, extended release, Tablet, multilayer, extended release - Oral
Hives
1.0 mg/mL, , 3.0 mg, 0.5 mg/mL, 2.0 mg/mL, 1.0 mg, 2.0 mg, 6.0 mg
Liquid - Oral, , Oral, Liquid, Tablet - Oral, Tablet, Syrup - Oral, Syrup, Solution / drops - Oral, Tablet, multilayer, Solution - Oral, Solution, Tablet, coated, Tablet, multilayer - Oral, Tablet, multilayer, extended release, Tablet, extended release - Oral, Tablet, coated - Oral, Solution / drops, Tablet, extended release, Tablet, multilayer, extended release - Oral
Catarrh
1.0 mg/mL, , 3.0 mg, 0.5 mg/mL, 2.0 mg/mL, 1.0 mg, 2.0 mg, 6.0 mg
Liquid - Oral, , Oral, Liquid, Tablet - Oral, Tablet, Syrup - Oral, Syrup, Solution / drops - Oral, Tablet, multilayer, Solution - Oral, Solution, Tablet, coated, Tablet, multilayer - Oral, Tablet, multilayer, extended release, Tablet, extended release - Oral, Tablet, coated - Oral, Solution / drops, Tablet, extended release, Tablet, multilayer, extended release - Oral
Hay Fever
1.0 mg/mL, , 3.0 mg, 0.5 mg/mL, 2.0 mg/mL, 1.0 mg, 2.0 mg, 6.0 mg
Liquid - Oral, , Oral, Liquid, Tablet - Oral, Tablet, Syrup - Oral, Syrup, Solution / drops - Oral, Tablet, multilayer, Solution - Oral, Solution, Tablet, coated, Tablet, multilayer - Oral, Tablet, multilayer, extended release, Tablet, extended release - Oral, Tablet, coated - Oral, Solution / drops, Tablet, extended release, Tablet, multilayer, extended release - Oral
Vasomotor Rhinitis
1.0 mg/mL, , 3.0 mg, 0.5 mg/mL, 2.0 mg/mL, 1.0 mg, 2.0 mg, 6.0 mg
Liquid - Oral, , Oral, Liquid, Tablet - Oral, Tablet, Syrup - Oral, Syrup, Solution / drops - Oral, Tablet, multilayer, Solution - Oral, Solution, Tablet, coated, Tablet, multilayer - Oral, Tablet, multilayer, extended release, Tablet, extended release - Oral, Tablet, coated - Oral, Solution / drops, Tablet, extended release, Tablet, multilayer, extended release - Oral
Allergic Conjunctivitis (AC)
1.0 mg/mL, , 3.0 mg, 0.5 mg/mL, 2.0 mg/mL, 1.0 mg, 2.0 mg, 6.0 mg
Liquid - Oral, , Oral, Liquid, Tablet - Oral, Tablet, Syrup - Oral, Syrup, Solution / drops - Oral, Tablet, multilayer, Solution - Oral, Solution, Tablet, coated, Tablet, multilayer - Oral, Tablet, multilayer, extended release, Tablet, extended release - Oral, Tablet, coated - Oral, Solution / drops, Tablet, extended release, Tablet, multilayer, extended release - Oral
Dermographism
1.0 mg/mL, , 3.0 mg, 0.5 mg/mL, 2.0 mg/mL, 1.0 mg, 2.0 mg, 6.0 mg
Liquid - Oral, , Oral, Liquid, Tablet - Oral, Tablet, Syrup - Oral, Syrup, Solution / drops - Oral, Tablet, multilayer, Solution - Oral, Solution, Tablet, coated, Tablet, multilayer - Oral, Tablet, multilayer, extended release, Tablet, extended release - Oral, Tablet, coated - Oral, Solution / drops, Tablet, extended release, Tablet, multilayer, extended release - Oral
Angioedema
1.0 mg/mL, , 3.0 mg, 0.5 mg/mL, 2.0 mg/mL, 1.0 mg, 2.0 mg, 6.0 mg
Liquid - Oral, , Oral, Liquid, Tablet - Oral, Tablet, Syrup - Oral, Syrup, Solution / drops - Oral, Tablet, multilayer, Solution - Oral, Solution, Tablet, coated, Tablet, multilayer - Oral, Tablet, multilayer, extended release, Tablet, extended release - Oral, Tablet, coated - Oral, Solution / drops, Tablet, extended release, Tablet, multilayer, extended release - Oral
Warnings
There are 20 known major drug interactions with Polaramine.Common Polaramine Drug Interactions
Drug Name
Risk Level
Description
Amitriptyline
Major
The metabolism of Amitriptyline can be decreased when combined with Dexchlorpheniramine maleate.
Amoxapine
Major
The metabolism of Amoxapine can be decreased when combined with Dexchlorpheniramine maleate.
Anagrelide
Major
The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Anagrelide.
Arsenic trioxide
Major
The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Arsenic trioxide.
Artemether
Major
The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Artemether.
Polaramine Toxicity & Overdose RiskOverdosing on a drug can cause decreased activity in the brain and nervous system.
Polaramine Novel Uses: Which Conditions Have a Clinical Trial Featuring Polaramine?
A total of 150 active trials are ongoing to ascertain the potential of Polaramine in alleviating Allergy, Dermographism and Catarrhal Symptoms.Condition
Clinical Trials
Trial Phases
Allergy
107 Actively Recruiting
Not Applicable, Phase 3, Phase 2, Phase 4, Phase 1, Early Phase 1
Dermographism
0 Actively Recruiting
Hay Fever
4 Actively Recruiting
Phase 2, Phase 1, Not Applicable
Angioedema
14 Actively Recruiting
Phase 2, Phase 3, Phase 1
Catarrh
1 Actively Recruiting
Phase 2
Vasomotor Rhinitis
0 Actively Recruiting
Hives
16 Actively Recruiting
Early Phase 1, Phase 3, Phase 2, Phase 4
Allergic Conjunctivitis (AC)
1 Actively Recruiting
Phase 1
Polaramine Reviews: What are patients saying about Polaramine?
5Patient Review
10/7/2009 Took this drug for years and it really worked. I stopped taking it and still haven't had any allergic reactions, which is amazing.
2.3Patient Review
7/5/2015 I was recommended this by my GP for mosquito bites, but it didn't work at all. The only upside is that it made me sleepy.
Patient Q&A Section about polaramine
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What are the side effects of Polaramine?
"The following side effects may occur: drowsiness, dizziness, constipation, stomach upset, blurred vision, or dryness of the mouth, nose, or throat. If you experience any of these side effects, tell your doctor or pharmacist immediately."
Answered by AI